Half of watchful waiting patients seek Tx in 3 years
Chicago-Watchful waiting is a common approach to prostate cancer, especially in patients who are in the later years of their life. A certain percentage of these men will wait, change their minds, and seek intervention. Extensive research efforts have been devoted to identifying predictors of outcomes after treatment with surgery or radiation therapy, but little is known about the outcome of watchful waiting during the PSA era.
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.